

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Richard Gallo et al.) Group Art Unit: To Be Assigned
Application No.: 10/575,537) Examiner: To Be Assigned
Filed: April 11, 2006) Confirmation No.:
For: HUMAN CATHELICIDIN) Certificate of Mailing
ANTIMICROBIAL PEPTIDES) I hereby certify that this paper is being deposited with
) the United States Postal Service via Express Mail Post
) Office to Addressee under 37 C.F.R. §1.10 on May 3,
) 2006 in an envelope addressed to Mail Stop PCT,
) Commissioner for Patents, P.O. Box 1450, Alexandria,
) VA 22313-1450.
) By: _____ Kim A. Cabello

FIRST INFORMATION DISCLOSURE STATEMENT

MAIL STOP PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. However, copies of the listed U.S. patents and U.S. patent application publications are not enclosed since it is no longer required according to the July 11, 2003 waiver of the requirement for copies of cited U.S. patents and U.S. patent application publications in national patent applications filed after June 30, 2003 and international applications entering the national stage under 35 U.S.C. § 371 after June 30, 2003.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

FIRST Information Disclosure Statement
Application No. 10/575,537
Attorney's Docket No. 1034123-000219
Page 2

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BUCHANAN INGERSOLL PC

Date May 3, 2006
By: Susan B. Fuller
Susan B. Fuller
Registration No. 51,979

P.O. Box 1404
Alexandria, Virginia 22313-1404
(858) 509-7300

Substitute for Form 1449A/PTO & 1449B/PTO				Complete If Known	
FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>				Application Number	10/575,537
				Filing Date	April 11, 2006
				First Named Inventor	Gallo et al.
				Examiner Name	
Sheet	1	of	3	Attorney Docket Number	1034123-000219

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Benincasa, Monica et al., "In vitro and in vivo antimicrobial activity of two alpha-helical cathelicidin peptides and of their synthetic analogs," <i>Peptides</i> , Vol. 24, No. 11, pp. 1723-1731, November 2003.
	Brasel, Kenneth et al., Hematologic Effects on flt3 Ligand in Vivo in Mice," <i>Blood</i> , Vol. 88, No. 6, pp. 2004-2012, 1996.
	<u>Clinical and Experimental Dermatology</u> Vol. 21, No. 3, pp.185, May 1996.
	Gallo, Richard L. et al., "Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse," <i>J. Biol. Chem.</i> , Vol. 272, No. 20, pp. 13088-93, May 16, 1997.
	Gennaro, Renato et al., "Pro-rich antimicrobial peptides from animals: structure, biological functions and mechanism of action," <i>Current Pharmaceutical Design</i> . Vol. 8, No. 9, pp. 763-78, 2002.
	Gennaro Renato et al., "Structural features and biological activities of the cathelicidin-derived antimicrobial peptides," <i>Biopolymers</i> , Vol. 55, No. 1, pp. 31-49, 2000.

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**FIRST
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

				Complete if Known
Sheet		2	of	3
Application Number	10/575,537			
Filing Date	April 11, 2006			
First Named Inventor	Gallo et al.			
Examiner Name				
Attorney Docket Number	1034123-000219			

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Gennaro, Renato et al., "Biological characterization of a novel mammalian antimicrobial peptide," <i>Biochimica et Biophysica Acta</i> , Vol. 1425, No. 2, pp. 361-8, October 23, 1998.
	Ha, Jong-Myung et al., "Synthesis and Antibiotic Activities of CRAMP, a Cathelin-related Antimicrobial Peptide and Its Fragments," <i>Bull. Korean Chem. Soc.</i> , Vol. 20, No. 9, pp. 1073-1077, 1999.
	Howell, Michael D. et al., "Selective Killing of <i>Vaccinia Virus</i> by LL-37: Implications for Eczema Vaccinatum," <i>Journal of Immunology</i> , Vol. 172, pp. 1763-1767, 2004.
	Johnson, B. Connor, "Posttranslational Covalent Modification of Proteins," Academic Press, NY, pp. 1-12 1983.
	Kaufman, Randal et al., "Synthesis, Processing, and Secretion of Recombinant Human Factor VIII Expressed in Mammalian Cells," <i>Journal of Biological Chemistry</i> Vol. 263, No. 13, pp. 6352-6362, 1988.
	Kaufman, Randal, "Selection and Coamplification of Heterologous Genes in Mammalian Cells" <i>Methods in Enzymology</i> , Vol. 185 pp. 527-566, 1990.
	McKinnon, P et al., "Expression, purification and characterization of secreted recombinant human insulin-like growth factor -I (IGF-I) and the potent variant des (1-3) IGF-I in Chinese hamster ovary cells" <i>Journal Molecular Endocrinology</i> 6, pp. 231-239, 1991.
	Merrifield, R.B., "Solid Phase Peptide Synthesis" <i>Journal. Am. Chem. Soc.</i> , Vol.85, pp. 2149, 1962.
	Ong, Peck et al., "Endogenous Antimicrobial Peptides And Skin Infections In Atopic Dermatitis," <i>New England Journal of Medicine</i> , Vol. 347, No. 15, pp. 1151-1160, October 10, 2002.
	Rattan, Suresh I. et al., "Protein Synthesis, Posttranslational Modifications, and Aging," <i>Annals of the N.Y. Academy of Science</i> , Vol. 663, pp.48-62 (1992).
	Sanchez et al., "Overexpression and structural study of the cathelicidin motif of the protegrin-3 precursor," <i>Biochemistry</i> , Vol. 41, No. 1, pp. 21-30, January 8, 2002.
	Scott, Jamie et al., "Searching for Peptide Ligands with an Epitope Library," <i>Science</i> Vol. 249, pp.386-390 (1990).
	Seifter, Sam et al., "Analysis for Protein Modifications and Nonprotein Cofactors," <i>Methods of Enzymology</i> , Vol. 182, pp. 626-646, 1990.
	Skerlavaj, Barbara et al., "Structural and functional analysis of horse cathelicidin peptides," <i>Antimicrobial Agents Chemotherapy</i> , Vol. 45, No. 3, pp. 715-22, March 2001.
	Smeianov, Vladimir et al. "Activity of cecropin P1 and FA-LL-37 Against urogenital microflora" <i>Microbes and Infection</i> , Vol. 2, pp. 773-777, 2000.
	Smith, George, et al., "Libraries of Peptides and Proteins Displayed on Filamentous Phage," <i>Methods Enzymology</i> , Vol. 217, pp. 228-257, 1993.
	Stewart, John, et al., "Solid Phase Peptides Synthesis," W.H. Freeman and Company, San Francisco, 1969, pp. 27-62.
	Tjabringa, G. Sandra et al., "The Antimicrobial Peptide LL-37 Activates Innate Immunity at the Airway Epithelial Surface by Transactivation of the Epidermal Growth Factor Receptor," <i>Journal of Immunology</i> , Vol. 171, pp. 6690-6696, 2003.
	Urlaub, Gail et al., "Isolation of Chinese Hamster cell mutants deficient in dihydrofolate reductase activity," <i>Proc Natl Acad Sci USA</i> , Vol. 77, pp. 4216-4220, 1980.
	Wood, Clive et al., "High Level Synthesis Of Immunoglobulins In Chinese Hamster Ovary Cells," <i>The Journal of Immunology</i> , Vo. 145, pp.3011-3016, 1990.
	Zaiou, Mohamed et al., "Antimicrobial and Protease Inhibitory Functions of the Human Cathelicidin (hCAP18/LL-37) Prosequence," <i>The Society for Investigative Dermatology</i> , Vol. 120, No. 5, pp. 810-816, May 2003.
	Zanetti, Margherita et al., "Cathelicidin peptides as candidates for a novel class of antimicrobials," <i>Current Pharmaceutical Design</i> , Vol. 8, No. 9, pp. 779-93, 2002.
	Zanetti, Margherita et al., "Structure and biology of cathelicidins," <i>Adv. Exp. Med. Biol.</i> , Vol. 479, pp. 203-218, 2000.

Examiner Signature	Date Considered
--------------------	-----------------

^aEXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

CA 103254.1

**FIRST
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

			<i>Complete If Known</i>	
Application Number	10/575,537			
Filing Date	April 11, 2006			
First Named Inventor	Gallo et al.			
Examiner Name				
Attorney Docket Number	1034123-000219			

Sheet	3	of	3	
-------	---	----	---	--

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Zanetti et al., "The cathelicidin family of antimicrobial peptide precursors: a component of the oxygen-independent defense mechanisms of neutrophils," Annals N. Y. Academy of Sciences, Vol. 832, pp. 147-62, December 15, 1997.
	Zanetti et al. "Cathelicidin Peptides as Candidates for a Novel Class of Antimicrobials" Current Pharmaceutical Design, Vol. 8, No. 9, pp 779-793, 2002

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
CA 103254.1